Biodexa Pharmaceuticals Plc (BDRX) ADR Each Representing 10000 Ord Shares SPON

Sell:$4.00Buy:$4.35$0.04 (0.93%)

Prices delayed by at least 15 minutes
Sell:$4.00
Buy:$4.35
Change:$0.04 (0.93%)
Deal now
Prices delayed by at least 15 minutes
Sell:$4.00
Buy:$4.35
Change:$0.04 (0.93%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Key people

Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Dmitry Zamoryakhin
Chief Scientific Officer, Chief Medical Officer
Daniel Palmer
Vice President - Technology
Nicola Tuckwell
Vice President, Head of Clinical Operations
Fiona Sharp
Group Controller
Steve Ellul
Chief Business Officer
Gary A. Shangold
Chief Medical Officer
Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Sijmen de Vries
Non-Executive Independent Director
Ann Merchant
Non-Executive Independent Director
Simon Turton
Senior Independent Non-Executive Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US59564R8079
  • Market cap
    $2.88m
  • Employees
    21
  • Shares in issue
    145.04m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.